Table 3.
New bacterial translation inhibitors in clinical use and in the pharmaceutical pipeline.
| Name | Class | Developer | Expected Activity Against CDC Urgent or WHO Critical Threat Pathogen | Innovativeness | Comments |
|---|---|---|---|---|---|
| Approved in US since 2017 | |||||
| Plazomicin (Zemdri) | Aminoglycoside | Achaogen | CRAB and CRE | WHO’s List of Essential Medicines (see Table 1) | |
| Omadacycline (Nuzyra) | Tetracycline | Paratek | MRSA | ||
| Lefamulin (Xenleta) | Pleuromutilin | Nabriva Therapeutics | MRSA | new chemical class with new mode of action | First pleuromutilin used for systemic treatment of bacterial infections in humans |
| Clinical Trial Phase 3 | |||||
| Contezolid/contezolid acefosamil | Oxazolidinone | MicuRx Pharmaceuticals Inc. | New drug application submitted (China NMPA) | ||
| Solithromycin | Macrolide (ketolide) | Toyama Chemical Co. Ltd. | Drug-resistant N. gonorrhoeae | ||
| Eravacycline (Xerava) | Tetracycline | Tetraphase | CRE and MRSA | Granted fast track designation by the FDA | |
| Clinical Trial Phase 2 | |||||
| Nafithromycin | Macrolide (ketolide) | Wockhardt | |||
| ARV-1801 (sodium fusidate) | Fusidic acid | Arrevus Inc. | MRSA | Approved for acute bacterial skin and soft tissue infections in markets outside the US | |
| Delpazolid (LCB01-0371) | Oxazolidinone | LegoChem Biosciences Inc./Nawei Biotechnology | Also in development for tuberculosis treatment | ||
| DNV3837/DNV3681 | Oxazolidinone-quinolone hybrid | Deinove SA | MDR Clostridioides difficile | ||
| Clinical Trial Phase 1 | |||||
| Apramycin (EBL-1003) | Aminoglycoside | Juvabis AG | CRAB and CRE | ||
| TP-271 | Tetracycline | La Jolla Pharmaceutical Company | CRAB and MDR Clostridioides difficile | No active studies, ongoing out-licensing | |
| TP-6076 | Tetracycline | La Jolla Pharmaceutical Company | CRAB and CRE | No active studies, ongoing out-licensing | |
| KBP-7072 | Tetracycline | KBP BioSciences Pharmaceutical Technical Co. Ltd. | CRAB | ||
CDC—Centers for Disease Control and Prevention; CRAB—carbapenem-resistant A. baumannii; CRE—carbapenem-resistant enterococci; FDA—Food and Drug Administration; MDR—multi-drug-resistant; MRSA—methicillin-resistant S. aureus; WHO—World Health Organization.